User:Jeremy S. Myers
From OpenWetWare
(Difference between revisions)
(→Contact Info) |
Current revision (11:20, 14 August 2008) (view source) |
||
| (11 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | |||
| - | |||
==Contact Info== | ==Contact Info== | ||
| - | [[Image:OWWEmblem.png|thumb|right| | + | [[Image:OWWEmblem.png|thumb|right|(an artistic interpretation)]] |
*Jeremy S. Myers, Ph.D. | *Jeremy S. Myers, Ph.D. | ||
*AstraZeneca Fellow | *AstraZeneca Fellow | ||
| + | *Advanced Targeted Proteomics Team Leader | ||
*Vanderbilt University School of Medicine | *Vanderbilt University School of Medicine | ||
*Mass Spectrometry Research Center | *Mass Spectrometry Research Center | ||
*Nashville, TN, U.S.A. | *Nashville, TN, U.S.A. | ||
| - | * | + | *jeremy.myers@vanderbilt.edu |
| - | + | for more information visit: http://www.advancedtargetedproteomics.com | |
==Education== | ==Education== | ||
<!--Include info about your educational background--> | <!--Include info about your educational background--> | ||
| - | * 2003 | + | * 2003-2007 Postdoctoral Fellow |
| - | * 1999 | + | * 2003 Ph.D., Louisiana State University |
| + | * 1999 B.S., Bucknell University | ||
==Research interests== | ==Research interests== | ||
<!-- Feel free to add brief descriptions to your research interests as well --> | <!-- Feel free to add brief descriptions to your research interests as well --> | ||
| - | # | + | # Targeted Mass Spectrometry-based Proteomics |
| - | + | # Targeted Therapeutics | |
| - | ==Publications== | + | ==Publications (since 2007)== |
| - | + | #Myers JS, Zhao R, Xu X, Ham AJ, Cortez D. Cyclin-dependent kinase 2 dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage. Cancer Res. 2007 Jul 15;67(14):6685-90. PMID: 17638878 | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
==Useful links== | ==Useful links== | ||
*[[OpenWetWare:Welcome|Introductory tutorial]] | *[[OpenWetWare:Welcome|Introductory tutorial]] | ||
*[[Help|OpenWetWare help pages]] | *[[Help|OpenWetWare help pages]] | ||
| + | |||
| + | ==Selected Protocols== | ||
| + | *[[Myers:EGFR_IP]] | ||
| + | *[[Myers:synchronization]] | ||
Current revision
Contents |
Contact Info
- Jeremy S. Myers, Ph.D.
- AstraZeneca Fellow
- Advanced Targeted Proteomics Team Leader
- Vanderbilt University School of Medicine
- Mass Spectrometry Research Center
- Nashville, TN, U.S.A.
- jeremy.myers@vanderbilt.edu
for more information visit: http://www.advancedtargetedproteomics.com
Education
- 2003-2007 Postdoctoral Fellow
- 2003 Ph.D., Louisiana State University
- 1999 B.S., Bucknell University
Research interests
- Targeted Mass Spectrometry-based Proteomics
- Targeted Therapeutics
Publications (since 2007)
- Myers JS, Zhao R, Xu X, Ham AJ, Cortez D. Cyclin-dependent kinase 2 dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage. Cancer Res. 2007 Jul 15;67(14):6685-90. PMID: 17638878



